0 Speaker List
 Scott  Gottlieb, M.D. Image

Scott Gottlieb, M.D.

Physician; Former Commissioner Food and Drug Administration (2017-2019); Former Senior Advisor – CMS; Regular CNBC Contributor

Travels From:
New York
Fee Range:
Inquire for Details

Scott Gottlieb, MD is a practicing physician and the 23rd Commissioner of Food and Drugs. A leading expert in health policy, Dr. Gottlieb’s work focuses on providing insights into the economic and technological forces driving the transformation of healthcare.

Dr. Gottlieb is widely published in leading medical journals and periodicals and has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and is a regular contributor to CNBC. In 2018 and again in 2019, Dr. Gottlieb was recognized by Fortune Magazine as one of “The World’s 50 Greatest Leaders” and by Time Magazine as one of the “50 People Transforming Healthcare.”

Featured Videos

A conversation with departing FDA Commissioner Scott Go ...

FDA Commissioner Dr. Scott Gottlieb Addresses Drug Pric ...

CNBC's full interview with former FDA Commissioner Scot ...

Speaker Resources


Scott Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improving medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He is a resident fellow at the American Enterprise Institute and a partner at the venture capital firm New Enterprise Associates.

Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines. Under his leadership, the FDA advanced new frameworks for the modern and safe and effective oversight of gene therapies, cell based regenerative medicines, targeted drugs, and digital health devices. The FDA implemented new reforms to standardize drug reviews and make historic improvements of post market data collection and the use of real-world evidence. They promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises.

Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. Dr. Gottlieb is widely published in leading medical journals and periodicals, including The Wall Street Journal, The New York Times, and The Washington Post. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and is a regular contributor to CNBC. Fortune Magazine recognized him as one of the “World’s 50 Greatest Leaders” in 2018 and again in 2019. In 2018 and then again in 2019 Modern Healthcare named Dr. Gottlieb the “Most Influential Physician Executive and Leaders” in its annual survey of 50 physician executives, and Time magazine named him one of its “50 People Transforming Healthcare in 2018.”

Speech Topics

How can the healthcare field successfully navigate the intersection of policy and medical innovation? How will policy developments in Washington related to the regulation and reimbursement of medical technology impact the ability to innovate and secure market access for beneficial new technologies. And what can those participating in the healthcare economy do to positively impact these trends.

The changing landscape for coverage of healthcare services and medical products is creating new challenges in making sure patients have affordable access to care, and that those financing these opportunities can sustain these investments. How we can develop sustainable models for covering the cost of new innovations and modernize our payment models; to make sure that patients have access to the medical care they need without bankrupting our healthcare system. What are the new models for healthcare delivery that we’ll need to embrace?

The ability to cure once intractable diseases is now at hand. Science has given us transformative new tools to arrest and reverse the underlying causes of once deadly diseases. What is this future of medical innovation, and how will we unlock the promise of new technologies like gene therapy, digital health, artificial intelligence, and regenerative medicine? What are the regulatory and reimbursement strategies that we’ll need to adopt to make sure these innovations reach patients, and what are the key scientific advances that are most likely to radically transform health outcomes and the delivery of medicine in the near future?

How does healthcare policy get made in in the nation’s capital? How are decisions reached, and what are the key variables that affect policymaking? Dr. Gottlieb will provide insights from the front lines of how some of the most important healthcare policies are made and address the outlook for the regulation and reimbursement of the healthcare sector.


Check Availability


  • "A de facto voice of reason in health care."

  • "A doctor, journalist and businessman just making plain sense…"

  • "He was terrific. You have a real asset in Scott and I hope we can work with you in the future."